Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Review

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

Authors: L Romayne Kurukulasuriya, James R Sowers

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Objectives

To summarize data supporting the effects of antidiabetes agents on glucose control and cardiovascular risk factors in patients with type 2 diabetes.

Methods

Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels, and blood pressure parameters are reviewed and summarized for the purpose of selecting optimal therapeutic regimens for patients with type 2 diabetes.

Results

National guidelines recommend the aggressive management of cardiovascular risk factors in patients with type 2 diabetes, including weight loss and achieving lipid and blood pressure treatment goals. All antidiabetes pharmacotherapies lower glucose; however, effects on cardiovascular risk factors vary greatly among agents. While thiazolidinediones, sulfonylureas, and insulin are associated with weight gain, dipeptidyl peptidase-4 inhibitors are considered weight neutral and metformin can be weight neutral or associated with a small weight loss. Glucagon-like peptide-1 receptor agonists and amylinomimetics (e.g. pramlintide) result in weight loss. Additionally, metformin, thiazolidinediones, insulin, and glucagon-like peptide-1 receptor agonists have demonstrated beneficial effects on lipid and blood pressure parameters.

Conclusion

Management of the cardiovascular risk factors experienced by patients with type 2 diabetes requires a multidisciplinary approach with implementation of treatment strategies to achieve not only glycemic goals but to improve and/or correct the underlying cardiovascular risk factors.
Appendix
Available only for authorised users
Literature
1.
2.
Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Heagerty AM, Malik RA: Diabetic cardiomyopathy--a distinct disease?. Best Pract Res Clin Endocrinol Metab. 2009, 23: 347-360. 10.1016/j.beem.2008.10.016.CrossRefPubMed
3.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y: Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009, 119: e21-e181. 10.1161/CIRCULATIONAHA.108.191261.CrossRefPubMed
4.
Pieske B, Wachter R: Impact of diabetes and hypertension on the heart. Curr Opin Cardiol. 2008, 23: 340-349. 10.1097/HCO.0b013e3283031ab3.CrossRefPubMed
5.
Sowers J, Stump C: Insights into the biology of diabetic vascular disease: what's new?. Am J Hypertens. 2004, 17: 2S-6S. 10.1016/j.amjhyper.2004.08.007.CrossRefPubMed
6.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321: 405-412. 10.1136/bmj.321.7258.405.PubMedCentralCrossRefPubMed
7.
Cefalu WT: Glycemic targets and cardiovascular disease. N Engl J Med. 2008, 358: 2633-2635. 10.1056/NEJMe0803831.CrossRefPubMed
8.
Kelly T, Bazzano L, Fonseca V, Theti T, Reynolds K, Jiang H: Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009, 151: 1-13.CrossRef
9.
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erquo S, Sattar N: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009, 373: 1765-1772. 10.1016/S0140-6736(09)60697-8.CrossRefPubMed
10.
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002, 106: 3143-3421.
11.
Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B: Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007, 30: 753-759. 10.2337/dc07-9920.CrossRefPubMed
12.
Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H: Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ). 2005, 128: 1-11.
13.
Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB: Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care. 2008, 31: 1582-1584. 10.2337/dc08-0025.PubMedCentralCrossRefPubMed
14.
Bays HE, Chapman RH, Grandy S: The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007, 61: 737-747. 10.1111/j.1742-1241.2007.01336.x.PubMedCentralCrossRefPubMed
15.
Anderson JW, Konz EC: Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001, 9 (suppl 4): 326S-334S. 10.1038/oby.2001.138.CrossRefPubMed
16.
Anderson JW, Kendall CW, Jenkins DJ: Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003, 22: 331-339.CrossRefPubMed
17.
Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjornsdottir S, Eliasson B: Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009, 52: 65-73. 10.1007/s00125-008-1190-x.CrossRefPubMed
18.
Kahn R, Robertson RM, Smith R, Eddy D: The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care. 2008, 31: 1686-1696. 10.2337/dc08-9022.PubMedCentralCrossRefPubMed
19.
Leiter LA, Fitchett D: Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist. Atheroscler Suppl. 2006, 7: 37-42. 10.1016/j.atherosclerosissup.2006.01.006.CrossRefPubMed
20.
American Association of Clinical Endocrinologists (AACE): Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007, 13 (suppl 1): 3-68.
21.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32: 193-203. 10.2337/dc08-9025.PubMedCentralCrossRefPubMed
22.
23.
Wing RR, Marquez B: Behavioral aspects of weight loss in type 2 diabetes. Curr Diab Rep. 2008, 8: 126-131. 10.1007/s11892-008-0023-0.CrossRefPubMed
24.
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz S: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009, 15: 541-559.CrossRef
25.
Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007, 298: 194-206. 10.1001/jama.298.2.194.CrossRefPubMed
26.
Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE: Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006, 29: 2137-2139. 10.2337/dc06-1120.CrossRefPubMed
27.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.CrossRef
28.
Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR: Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006, 49: 1761-1769. 10.1007/s00125-006-0297-1.CrossRefPubMed
29.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359: 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed
30.
Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF: Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther. 2009, 34: 13-23. 10.1111/j.1365-2710.2008.00984.x.CrossRefPubMed
31.
Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008, 372: 1240-1250. 10.1016/S0140-6736(08)61206-4.CrossRefPubMed
32.
Hoogwerf BJ, Doshi KB, Diab D: Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008, 4: 355-362.PubMedCentralPubMed
33.
Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ: Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol. 2000, 40: 49-57. 10.1177/00912700022008694.CrossRefPubMed
34.
Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P: Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007, 55: 62-68. 10.2310/6650.2007.06036.CrossRefPubMed
35.
Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. 2006, 4: CD005061.PubMed
36.
Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N: The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev. 2008, 4: 340-356. 10.2174/157339908786241133.CrossRefPubMed
37.
Zinman B: PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab. 2001, 3 (suppl 1): S34-S43. 10.1046/j.1463-1326.2001.00033.x.CrossRefPubMed
38.
Kawai T, Funae O, Shimada A, Tabata M, Hirata T, Atsumi Y, Itoh H: Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Intern Med. 2008, 47: 1181-1188. 10.2169/internalmedicine.47.0969.CrossRefPubMed
39.
Miyazaki Y, DeFronzo RA: Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab. 2008, 10: 1204-1211.PubMed
40.
Norris SL, Carson S, Roberts C: Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diabetes Rev. 2007, 3: 127-140. 10.2174/157339907780598216.CrossRefPubMed
41.
Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T: Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med. 2005, 22: 980-985. 10.1111/j.1464-5491.2005.01656.x.CrossRefPubMed
42.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004, 27: 2628-2635. 10.2337/diacare.27.11.2628.CrossRefPubMed
43.
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009, 374: 39-47. 10.1016/S0140-6736(09)60659-0.CrossRefPubMed
44.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005, 28: 1092-1100. 10.2337/diacare.28.5.1092.CrossRefPubMed
45.
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005, 28: 1083-1091. 10.2337/diacare.28.5.1083.CrossRefPubMed
46.
Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008, 24: 275-286.CrossRefPubMed
47.
Zinman B, Hoogwerf BJ, Duran GS, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG: The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007, 146: 477-485.CrossRefPubMed
48.
Drucker D, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, for the DURATION-1-Study Group: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, noninferiority study. Lancet. 2008, 372: 1240-1250. 10.1016/S0140-6736(08)61206-4.CrossRefPubMed
49.
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009, 373: 473-481. 10.1016/S0140-6736(08)61246-5.CrossRefPubMed
50.
Madsbad S: Liraglutide Effect and Action in Diabetes (LEAD) trial. Expert Rev Endocrinol Metab. 2009, 4: 119-129. 10.1586/17446651.4.2.119.CrossRef
51.
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009, 32: 84-90. 10.2337/dc08-1355.PubMedCentralCrossRefPubMed
52.
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L: Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009, 32: 1224-1230. 10.2337/dc08-2124.PubMedCentralCrossRefPubMed
53.
Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006, 368: 1696-1705. 10.1016/S0140-6736(06)69705-5.CrossRefPubMed
54.
Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005, 78: 675-688. 10.1016/j.clpt.2005.09.002.CrossRefPubMed
55.
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006, 29: 2632-2637. 10.2337/dc06-0703.CrossRefPubMed
56.
DeFronzo RA, Hissa MN, Garber AJ, Luiz GJ, Yuyan DR, Ravichandran S, Chen RS: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009, 32: 1649-1655. 10.2337/dc08-1984.PubMedCentralCrossRefPubMed
57.
Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M: Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008, 24: 537-550. 10.1185/030079908X260925.CrossRefPubMed
58.
Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004, 27: 256-263. 10.2337/diacare.27.1.256.CrossRefPubMed
59.
60.
61.
Yilmaz H, Gursoy A, Sahin M, Guvener DN: Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol. 2007, 44: 187-192. 10.1007/s00592-007-0004-9.CrossRefPubMed
62.
Kusaka I, Nagasaka S, Horie H, Ishibashi S: Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?. Diabetes Obes Metab. 2008, 10: 1039-1046. 10.1111/j.1463-1326.2008.00857.x.CrossRefPubMed
63.
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006, 49: 2564-2571. 10.1007/s00125-006-0416-z.CrossRefPubMed
64.
Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R: Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009, 25: 2401-2411. 10.1185/03007990903178735.CrossRefPubMed
65.
Scott R, Loeys T, Davies MJ, Engel SS: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008, 10: 959-969. 10.1111/j.1463-1326.2007.00839.x.CrossRefPubMed
66.
Bergenstal R, Kim T, Trautmann M, Zhuang D, Okerson T, Taylor K: Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes (abstract no. LAR-105). Circulation. 2008, 118.
67.
Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O: Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract. 2008, 14: 993-999.CrossRefPubMed
68.
DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L: Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008, 24: 2943-2952. 10.1185/03007990802418851.CrossRefPubMed
69.
Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG, for the Pramlintide in Type 2 Diabetes Group: Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care. 1998, 21: 987-993. 10.2337/diacare.21.6.987.CrossRefPubMed
70.
Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Wyer C: Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004, 12: 661-668. 10.1038/oby.2004.76.CrossRefPubMed
71.
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007, 115: 114-126. 10.1161/CIRCULATIONAHA.106.179294.CrossRefPubMed
72.
Granberry MC, Fonseca VA: Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs. 2005, 5: 201-209. 10.2165/00129784-200505030-00006.CrossRefPubMed
73.
Steiner G: A new perspective in the treatment of dyslipidemia: can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?. Treat Endocrinol. 2005, 4: 311-317. 10.2165/00024677-200504050-00004.CrossRefPubMed
74.
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternack RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110: 227-239. 10.1161/01.CIR.0000133317.49796.0E.CrossRefPubMed
75.
Papanas N, Tziakas D, Chalikias G, Floros D, Trypsianis G, Papadopoulou E, Kortsaris A, Symeonidis G, Souliou E, Maltezos E, Hatseras D: Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes Metab. 2006, 32: 344-349. 10.1016/S1262-3636(07)70289-6.CrossRefPubMed
76.
Sliwinska A, Blasiak J, Kasznicki J, Drewoski J: In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). Chem Biol Interact. 2008, 173: 159-165. 10.1016/j.cbi.2008.03.017.CrossRefPubMed
77.
Koshiba K, Nomura M, Nakaya Y, Ito S: Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest. 2006, 53: 87-94. 10.2152/jmi.53.87.CrossRefPubMed
78.
Manzella D, Grella R, Abbatecola AM, Paolisso G: Repaglinide adminstration improves brachial reactivity in type 2 diabetic patients. Diabetes Care. 2005, 28: 366-371. 10.2337/diacare.28.2.366.CrossRefPubMed
79.
Johansen OE, Birkeland KI: Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs. 2007, 7: 319-335. 10.2165/00129784-200707050-00002.CrossRefPubMed
80.
Yngen M, Ostenson CG, Hjemdahl P, Wallén NH: Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med. 2006, 23: 134-140. 10.1111/j.1464-5491.2005.01765.x.CrossRefPubMed
81.
Esposito K, Giugliano D, Nappo F, Marfella R, for the Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004, 110: 214-219. 10.1161/01.CIR.0000134501.57864.66.CrossRefPubMed
82.
Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT: The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004, 256: 1-14. 10.1111/j.1365-2796.2004.01328.x.CrossRefPubMed
83.
Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A Study of two ethnic groups. Diabetes Care. 1993, 16: 621-629. 10.2337/diacare.16.4.621.CrossRefPubMed
84.
Derosa G, Fogari E, Cicero AFG, D'angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SAT, Gravina A, Ferrari I, Fogari R: Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007, 30: 387-394. 10.1291/hypres.30.387.CrossRefPubMed
85.
Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM: Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA. 2009, 302: 1186-1194. 10.1001/jama.2009.1347.CrossRefPubMed
86.
De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD: Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005, 257: 100-109. 10.1111/j.1365-2796.2004.01420.x.CrossRefPubMed
87.
Karagiannis E, Pfutzner A, Forst T, Lubben G, Roth W, Grabellus M, Flannery M, Schondorf T: The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther. 2008, 10: 206-212. 10.1089/dia.2008.0244.CrossRefPubMed
88.
Abbasi F, Lima NK, Reaven GM: Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism. 2009, 58: 373-378. 10.1016/j.metabol.2008.10.011.CrossRefPubMed
89.
Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control. J Am Coll Cardiol. 2005, 45: 1925-1931. 10.1016/j.jacc.2005.03.041.CrossRefPubMed
90.
Papanas N, Maltezos E: Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?. Curr Pharm Design. 2009, 15: 3179-3192. 10.2174/138161209789057995.CrossRef
91.
Kalaitzidis RG, Sarafidis PA, Bakris GL: Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Design. 2009, 15: 529-536. 10.2174/138161209787315693.CrossRef
92.
Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T: Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol. 2007, 49: 290-297. 10.1016/j.jacc.2006.08.054.CrossRefPubMed
93.
Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006, 29: 554-559. 10.2337/diacare.29.03.06.dc05-0695.CrossRefPubMed
94.
Maggs D, Bhole D, Yan P, Stonehouse A, Brodows R, Okerson T: Exenatide is superior to insulin in attaining tight glycaemic control (HbA1c ≤ 6.5%) with a more favourable accompanying metabolic profile (abstract no. 876). Program and abstracts of the European Association for the Study of Diabetes (EASD) 44th Annual Meeting; September 7-11. 2008, ; Rome, Italy
95.
Okerson T, Yan P, Stonehouse A, Brodows R, Bhole D: Exenatide improved systolic blood pressure compared to insulin or placebo in patients with type 2 diabetes (abstract no. 877). Program and abstracts of the European Association for the Study of Diabetes (EASD) 44th Annual Meeting; September 7-11. 2008, ; Rome, Italy
96.
Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR: Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract. 2007, 77: 180-187. 10.1016/j.diabres.2006.12.011.CrossRefPubMed
97.
Bergenstal R, Kim T, Trautmann M, Okerson T, Taylor K: Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes (abstract no. 1239). Circulation. 2008, 118: S1086.
98.
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF: Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010, 12: 233-240. 10.1089/dia.2009.0141.CrossRefPubMed
99.
Pettigrew KA, McKnight AJ, Martin RJ, Patterson CC, Kilner J, Sadliert D, Maxwell AP, Savage DA, for the Warren 3/UK GoKinD Study Group: Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabetic Med. 2008, 25: 1129-1131. 10.1111/j.1464-5491.2008.02540.x.CrossRef
100.
Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA: Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008, 48: 592-598. 10.1177/0091270008316885.CrossRefPubMed
101.
Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T: Acarbose slows progression of intimamedia thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004, 35: 1073-1078. 10.1161/01.STR.0000125864.01546.f2.CrossRefPubMed
102.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003, 290: 486-494. 10.1001/jama.290.4.486.CrossRefPubMed
Metadata
Title
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
Authors
L Romayne Kurukulasuriya
James R Sowers
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-45

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue

Original investigation

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study

Original investigation

The combined effects of sidestream smoke extracts and glycated serum albumin on endothelial cells and platelets

Original investigation

Palmitate and insulin synergistically induce IL-6 expression in human monocytes

Original investigation

Eight week exposure to a high sugar high fat diet results in adiposity gain and alterations in metabolic biomarkers in baboons (Papio hamadryas sp.)

Original investigation

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

Original investigation

Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits